SCHEMBL21451071

SCHEMBL21451071

CCCNc1nc2ccccc2c2c(=O)c3cc(F)ccc3sc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MERTK Q12866 1/20 0.45
TLR7 Q9NYK1 1/20 0.41
APP P05067 4/20 0.41
PDE5A O76074 1/20 0.40
ALDH1A1 P00352 2/20 0.40
ELANE P08246 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX12 P18054 1/20 0.38
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
BCHE P06276 2/20 0.38
ACHE P22303 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30089833 0.91 GLA (0.36) MERTKAPPMAPTBCHEACHE
SCHEMBL21875228 0.91 GLA (0.36) MERTKAPPMAPTBCHEACHE
SCHEMBL21451072 0.90 KDM4E (0.42) ALDH1A1KDM4EMAPTMEN1CYP2C19
SCHEMBL21875232 0.90 PRKCI (0.38) MERTKAPPKDM4EMAPTGLA
SCHEMBL30089850 0.90 PRKCI (0.38) MERTKAPPKDM4EMAPTGLA
SCHEMBL21451023 0.89 FLT3 (0.47) TOP2ASLC2A1FLT3
SCHEMBL30089855 0.89 HDAC3 (0.36) MERTKGLATOP1TOP2AKCNH2
SCHEMBL21451010 0.89 HDAC3 (0.36) MERTKGLATOP1TOP2AKCNH2
SCHEMBL21450997 0.89 CYP1A2 (0.44) PDE5AALDH1A1KDM4EMAPTMEN1
SCHEMBL30089840 0.89 FLT3 (0.47) TOP2ASLC2A1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 MERTK 17/4885TLR7 1732/4885APP 4336/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 MERTK 17/4885TLR7 1732/4885APP 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.